Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Imaging of the Urachus
Zulfiqar, Maria , Brown, Parker J. , Chughtai, Komal , Navale, Pooja , Tan, Nelly , Yano, Motoyo , Aamir, Asmaa, Tassel, Dane Van , Siegel, Cary , Kawashima, Akira , Van Tassel, Dane , Siegel, Cary Lynn , Kawashima, Akira , Zulfiqar, Maria

RadioGraphics | April 10, 2025 | Volume: 45 | Issue: 5 | Pages: No page available

10.1148/rg.240122 | PMID 40208809 Get It

Frequently overlooked yet clinically significant, the urachus can exhibit a diverse range of pathologic conditions, which can pose a diagnostic challenge at imaging for the radiologist and which require a thorough understanding of urachal embryogenesis.
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia
Chanan‐Khan, Asher , Xue, Mei , Massoudi, Marjan , Balk, Mark, Gani, Ray , Piran, Hossein Zivari, Yang, Keri, Hanna, Kirollos S.

Journal of Managed Care & Specialty Pharmacy | April 10, 2025 | Volume: 31 | Issue: 5 | Pages: 482-490

10.18553/jmcp.2025.24330 | PMID 40207898 Get It

WITHDRAWN: Spatial Analysis of Placentae During Congenital Cytomegalovirus Infection Reveals Distinct Cellular Profiles in Immune Cells and Trophoblasts
Sintim-Aboagye, Elise, Sherman, W.B., Farnan, Sheila, Otrubova, Kamila, Verma, N, Littlefield, Dawn, Punia, Sohan, Blackstad, Mark, Schleiss, Mark R. , Enninga, Elizabeth Ann L. , Chakraborty, Rana , Quach, Huy Quang , Sherman, Will, Verma, Namisha, Schleiss, Mark R , Enninga, Elizabeth Ann L , Sherman, Will, Verma, Namisha, Johnson, Erica L. , Norgan, Andrew P. , Gray, Clive M.

No container title available | April 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.04.647170 | PMID 40291677 Get It

Withdrawal Statement The authors have withdrawn the manuscript because the data it contained has been updated. Consequently, they request that this work should not be cited as a reference for any projects to ensure the use of the most current information. For any questions or further clarifications, readers are encouraged to contact the corresponding author directly
UAE Consensus on Patient Profiles for Pre-exposure Prophylaxis with Monoclonal Antibodies against COVID-19 in Hematological Malignancies and Immunocompromised States
Hashmi, Shahrukh K. , Abdalla, Jehad , Alam, Arif, Abuhaleeqa, Mohamed , Mehiri, Amna Al, Lal, Amar , Osman, Hani, Kaloyannidis, Panayotis , George, Biju

New Emirates Medical Journal | April 10, 2025 | Volume: 05 | Issue: No issue available | Pages: No page available

10.2174/0102506882347591250115073949 Get It

Introduction: Despite significant advancements in COVID-19 treatment and prevention, immunocompromised individuals, particularly those with hematological malignancies, remain at high risk for severe infection and suboptimal vaccine response. Pre-exposure prophylaxis strategies for these vulnerable populations have been limited. Monoclonal antibodies, proteins designed to target specific antigens, offer a promising preventive solution for individuals unable to mount a sufficient immune response to vaccination. However, there is a critical unmet need to establish clear patient selection criteria for pre-exposure prophylaxis with monoclonal antibodies in these groups. This consensus statement explores recent research to address this gap, outlining profiles of patients most likely to benefit from monoclonal antibody-based prophylaxis. Methodology: The consensus statement was developed through a rigorous process, utilizing a pre-Delphi search method and a modified Delphi technique to gather expert opinions. This approach ensured a comprehensive and informed consensus among experts in the field. Initially, nine distinct patient categories requiring pre-exposure prophylaxis with monoclonal antibodies were identified. Through iterative rounds of expert feedback, discussion, and refinement, these nine categories were expanded and subdivided into twelve more specific groups of hematological malignancies and immunocompromised disorders. This refinement aimed to better capture the diverse patient profiles requiring prophylaxis, providing a more detailed framework for the targeted administration of monoclonal antibodies. Results: The study resulted in the panel members agreeing on nine categories for the use of monoclonal antibodies in COVID-19 prevention for high-risk patients. Achieving consensus among experts is crucial as it reflects the collective validation of evidence-based recommendations that can be reliably applied in clinical practice. A 100% agreement was reached for HIV and AIDS, underscoring the unanimous recognition of the vulnerability of this group to severe COVID-19 outcomes. Similarly, 96% agreement was reached for patients on immunomodulatory drugs (IMiDs), and 90.5% for those with hematological diseases, highlighting strong expert support for prophylaxis in these categories. Immunodeficiencies and renal conditions garnered 86% agreement, indicating broad, although slightly more varied, expert consensus on these groups. Lastly, 80% of the panel supported patients with solid organ cancer, liver conditions, rare neurological disorders, and severe life-limiting neuro-disabilities, reflecting recognition of their elevated risk despite more diverse opinions for these categories. Conclusion: This consensus statement offers healthcare professionals in the UAE a clear, evidence-based framework for the use of monoclonal antibodies in preventing COVID-19 among patients with hematological malignancies and immunocompromised conditions. By outlining specific patient categories, the statement provides a practical guide that enables clinicians to make informed decisions about pre-exposure prophylaxis, ensuring that high-risk individuals receive timely and appropriate protection. The consensus not only enhances the ability of healthcare providers to identify and prioritize at-risk populations, but also optimizes patient outcomes by streamlining preventive measures in clinical practice. In addition, these findings lay the groundwork for future research and the development of standardized protocols, ultimately improving the management of vulnerable populations in the ongoing fight against COVID-19.
Radiomics-Based Prediction of Local Recurrence after Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer
Ogbonna, Chioma P, Breen, William G. , Noach, P., Rajagopalan, Srinivasan , Hostetter, Logan , Maldonado, Fabien , Bartholmai, Brian J. , Merrell, Kenneth W. , Peikert, T., Bartholmai, Brian J

Annals of the American Thoracic Society | April 10, 2025 | Volume: 22 | Issue: 8 | Pages: 1236-1243

10.1513/annalsats.202410-1047oc | PMID 40208641 Get It

Abstract Rationale Stereotactic body radiation therapy (SBRT) represents an effective therapeutic strategy for early-stage non–small cell lung cancer (NSCLC); however, local and systemic recurrences represent ongoing challenges. Computed tomography (CT) radiomics-based risk models can potentially be used to predict the risk of local recurrence on pretreatment CT scans. Objective Development of a radiomics model to predict local recurrence after SBRT in patients with NSCLC. Methods This single-institution study includes a retrospective case-control training set (20 patients with local recurrence and 40 control subjects) and an independent validation set (198 consecutive cases) of patients with early-stage NSCLC treated with SBRT. Tumors were semiautomatically segmented, and 102 quantitative radiomic features, including texture, landscape, spatial, nodule shape, and nodule surface features, were extracted. These features were included in three separate multivariable models to predict the risk of recurrence on the basis of pre-SBRT, post-SBRT, and the difference between the pre-SBRT and post-SBRT scans (Delta model). The pre-SBRT model was subsequently validated in an independent validation set. Results Thirteen independent variables were selected for the models using the Boruta algorithm. The sensitivity, specificity, and area under the curve of the pre-SBRT, post-SBRT, and Delta models were 85%, 90%, and 0.91; 85%, 92.5%, and 0.92; and 85%, 92.5%, and 0.94, respectively. The pre-SBRT model was validated in the independent validation set (area under the curve, 0.89; confidence interval, 0.83–0.92), because this model was believed to be the most useful to assist in individualized treatment planning. Conclusions Radiomic analysis facilitated the development of three high-performing models predicting local recurrence using either pre-SBRT CT, post-SBRT CT, or the change between these two. We successfully validated the most clinically relevant model, the pre-SBRT model. Although this model needs further validation, it may facilitate individualized surveillance, treatment planning, and selection of adjuvant therapy.
Noninvasive brain stimulation as focal epilepsy treatment in the hospital, clinic, and home
Islam, Karimul , Starnes, Keith , Smith, Kelsey M. , Gregg, Nicholas M. , Worrell, Gregory A. , Lundstrom, Brian N. , Richner, Thomas, Gregg, Nicholas M , Worrell, Gregory A , Lundstrom, Brian Nils , Smith, Kelsey M , Starnes, Donnie Keith , Islam, Karimul , Richner, Thomas J. , Rabinstein, Alejandro A.

Epilepsia Open | April 10, 2025 | Volume: 10 | Issue: 3 | Pages: 787-795

10.1002/epi4.70033 | PMID 40208019 Get It

Abstract Objective Noninvasive brain stimulation (NIBS) provides a treatment option for patients not eligible for surgical intervention or who seek low‐risk approaches and may be used in the hospital, clinic, and at home. Our objective is to summarize our single‐center experience with multiple NIBS approaches for the treatment of focal epilepsy. Methods A retrospective chart review identified drug‐resistant focal epilepsy patients who received NIBS as an epilepsy treatment at Mayo Clinic in Rochester, MN. Patients were typically treated as follows: (1) for TMS, 1 Hz stimulation was applied for five consecutive days in the neuromodulation clinic, (2) for outpatient tDCS, stimulation was applied for five consecutive days in the clinic, followed by optional treatment at home, and (3) for inpatient tDCS, stimulation was applied for three consecutive days. We analyzed continuous EEG data for the inpatient tDCS cohort and available HD‐EEG data for outpatient cohorts to quantify changes in interictal epileptiform discharges (IEDs) as a result of stimulation. Outcomes were assessed at 1 month for TMS and outpatient tDCS and 1 week for inpatient tDCS. Results Twenty‐four patients were treated with TMS ( n = 10) and tDCS ( n = 14, 9 as outpatients). The median age was 40 years (range 15–73). The median seizure reduction following stimulation was 50%. Fourteen patients (58%) were responders to treatment (TMS = 4/10, tDCS Outpatient = 7/9, tDCS Inpatient = 3/5). Five outpatient tDCS participants elected to continue treatment at home. Four TMS and four outpatient tDCS patients underwent high‐density EEG before and after 5 days of therapy. Following stimulation, IED rate was reduced in 4/5 inpatient tDCS patients, 4/4 outpatient tDCS patients, and 4/4 TMS patients. Two patients experienced an increase in seizure frequency (1 following TMS and 1 following outpatient tDCS), which returned to baseline 4–6 weeks after stimulation treatments were discontinued. Significance TMS and tDCS are potential treatment approaches for drug‐resistant focal epilepsy patients in the hospital, clinic, and home. They have a favorable safety profile and can lead to a reduction in IED rates and seizures. These results suggest further studies are needed to examine NIBS as a treatment for epilepsy. Plain Language Summary Noninvasive brain stimulation, such as transcranial magnetic stimulation and transcranial direct current stimulation, offers new treatment options for patients with focal seizures. This study reviewed the experience at Mayo Clinic using noninvasive brain stimulation in the hospital, clinic, and at‐home settings to treat seizures. The results showed an overall 50% median seizure reduction, and 58% of patients had at least a 50% reduction in seizures. Noninvasive brain stimulation is a promising treatment approach with a favorable safety profile.
The Effect of Relugolix Combination Therapy in Black/African American Women with Uterine Fibroids
Schulmann, Thierry, Venable, Sateria, Stewart, E A , Stewart, Elizabeth A.

Journal of Obstetrics and Gynaecology | April 10, 2025 | Volume: 45 | Issue: 1 | Pages: No page available

10.1080/01443615.2025.2487106 | PMID 40207912 Get It

Retrospective Pilot Study: Squamous Cell Carcinoma in Situ of the Head and Neck Treated With Topical 5-Fluorouracil
Kumar, Anagha , Asamoah, Eucabeth, Baum, Christian L.

Dermatologic Surgery | April 10, 2025 | Volume: 51 | Issue: 9 | Pages: 898-900

10.1097/dss.0000000000004643 | PMID 40207780 Get It

Utility of Nasal Debridement Following Pediatric Functional Endoscopic Sinus Surgery: A Scoping Review
Kim, Jeeho D. , Valencia‐Sanchez, Bastien A. , Hsia, Beau , Alshaka, Saif, Bitar, Gabriel , Patel, Vijay A. , Patel, Vijay A , Hsia, Beau

Sinusitis | April 10, 2025 | Volume: 9 | Issue: 1 | Pages: 6

10.3390/sinusitis9010006 Get It

The role of second-look endoscopy and debridement (SLED) remains uncertain in children due to the perceived need for additional general anesthesia following their initial functional endoscopic sinus surgery (FESS) while mitigating risks and healthcare costs. This comprehensive review synthesizes current evidence on SLED in children, focusing on its practice pattern and treatment outcomes. This review was designed and performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews Protocol. Independent queries of the PubMed Central, MEDLINE, and Bookshelf databases were performed. A total of 53 relevant, unique articles were initially identified; 12 articles were ultimately deemed appropriate for inclusion in final analysis. The most common indication for FESS was chronic rhinosinusitis or recurrent sinus infections while that for SLED under general anesthesia varied from institutional practice patterns to surgeon preference. No meaningful comparison of outcomes was possible as the “success rates” of FESS with or without SLED were largely based on unvalidated questionnaires and equally subjective surgeon assessments. Even when looking at outcomes based on revision rates, FESS with SLED was considered successful between 60.5% and 95.6% of the time, with a mean of 84.2%, while FESS without SLED was successful between 71.0% to 96.4% of the time, with a mean of 86.3%. However, no randomized, controlled studies were available in the pediatric literature pertaining to FESS with or without SLED. Moreover, it became apparent that previous conclusions on the utility of SLED were based on the outcomes of FESS following one single SLED under general anesthesia vs. no SLED. As such, there is an unmet need to examine the utility of serial, office-based SLED in children to better elucidate its utility in pediatric FESS.